| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-43411-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-664SS | |||
| BSA Free | NB100-664 | |||
| Azide and BSA Free | NBP2-81007 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-725 | |||
| BSA Free | NB100-725SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27293 | |||
| BSA Free | NBP2-27293SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB847R-100 | |||
| Carrier Free | MAB847R-SP | |||
| Carrier Free | IC847RU-100UG | |||
| Carrier Free | IC847RR-100UG | |||
| Carrier Free | IC847RS-100UG | |||
| Carrier Free | IC847RG-100UG | |||
| Carrier Free | IC847RT-100UG | |||
| Carrier Free | IC847RN-100UG | |||
| Carrier Free | IC847RV-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-29626SS | |||
| BSA Free | NBP2-29626 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC2932V-100UG | |||
| Carrier Free | IC2932U-100UG | |||
| Carrier Free | IC2932T-100UG | |||
| Carrier Free | IC2932S-100UG | |||
| Carrier Free | IC2932R-100UG | |||
| Carrier Free | IC2932N-100UG | |||
| Carrier Free | IC2932G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC2932V-100UG | |||
| Carrier Free | IC2932U-100UG | |||
| Carrier Free | IC2932T-100UG | |||
| Carrier Free | IC2932S-100UG | |||
| Carrier Free | IC2932R-100UG | |||
| Carrier Free | IC2932N-100UG | |||
| Carrier Free | IC2932G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC2932V-100UG | |||
| Carrier Free | IC2932U-100UG | |||
| Carrier Free | IC2932T-100UG | |||
| Carrier Free | IC2932S-100UG | |||
| Carrier Free | IC2932R-100UG | |||
| Carrier Free | IC2932N-100UG | |||
| Carrier Free | IC2932G-100UG | |||
![Immunohistochemistry: LYVE-1 Antibody (ALY7) [NBP1-43411] - Immunohistochemistry of cryosections of mouse intestine at 2.5 ug/ml of anti-mouse LYVE-1 antibody followed by Anti-Rat IgG Rhodamine (right). Phase image of same field (left).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-ALY7-Immunohistochemistry-NBP1-43411-img0004.jpg "Immunohistochemistry: LYVE-1 Antibody (ALY7) [NBP1-43411] - Immunohistochemistry of cryosections of mouse intestine at 2.5 ug/ml of anti-mouse LYVE-1 antibody followed by Anti-Rat IgG Rhodamine (right). Phase image of same field (left).")
![Flow Cytometry: LYVE-1 Antibody (ALY7) [NBP1-43411] - Analysis using the Biotin conjugate of NBP1-43411. Staining of LYVE-1 transfected cells with 0.06 ug of Rat IgG1 k Isotype Control Biotin (blue histogram) or 0.06 ug of Anti-Mouse Lyve-1 Biotin (purple histogram) followed by Streptavidin PE.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-ALY7-Flow-Cytometry-NBP1-43411-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] - Ang II treatment promotes lymphatic marker expression of LECs in vitro. (A) Immunofluorescence staining of LECs with anti-LYVE-1 & anti-VEGFR-3 antibodies. (B) LECs were treated with Ang II (500 nM) for 12 & 24 h, the mRNA levels of LYVE-1, VEGFR-3 & Prox1 were detected by qPCR, & the data were normalized using the reference gene GAPDH (n = 6). (C) The protein expression level of VEGFR-3 was measured by immunoblotting & normalized using beta -actin (n = 4). The results are expressed as the means ± SD, & n represents the number of independent experiments. *P < 0.05, **P < 0.01, & ***P < 0.001 versus Control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33013481), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43411_rat-monoclonal-lyve-1-antibody-aly7-310202415171341.jpg)
![Immunocytochemistry/ Immunofluorescence: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] - Ang II infusion increases cardiac lymphangiogenesis via AT1R in vivo. (A) Wild-type mice were subcutaneously infused with Ang II (1,000 ng/kg/min) with or without losartan (10 mg/kg) for 1 or 2 weeks, & the systolic blood pressure was measured by the tail-cuff method (n = 6). (B) Cardiac mRNA expression level of LYVE-1 was measured by qPCR analysis (n = 3). (C) Cardiac mRNA expression level of VEGFR-3 was measured by qPCR analysis (n = 3). (D) Immunofluorescence staining of hearts with anti-LYVE-1 (Red) & anti- VEGFR-3 (Green) antibodies & DAPI (Blue) (Left, n = 6), & the quantification of the LYVE-1+ & Prox1+ lymphatic vessels in the hearts (Right, n = 6). The results are expressed as the means ± SD, & n represents the number of independent experiments. *P < 0.05, **P < 0.01, & ***P < 0.001 versus Sham group; #P < 0.05, ##P < 0.01, & ###P < 0.001 versus Ang II 1W + Saline group; $$$P < 0.001 versus Ang II 2W + Saline group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33013481), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43411_rat-monoclonal-lyve-1-antibody-aly7-310202416165617.jpg)
![Immunocytochemistry/ Immunofluorescence: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] - Molecular characterization of LECs in the SCS ceiling with RNA FISH.(A-B) Expression of new cLEC/cluster 2 marker genes Ackr3 (A) & Btnl9 (B) by RNA sequencing (left panels) & RNA FISH (right panels). As GFP fluorescence is lost during tissue processing for RNA FISH, immunofluorescence staining for ANXA2 (red) & LYVE1 (green) served as markers for cLECs & fLECs, respectively. Arrows point to cLECs expressing Ackr3 & Btnl9 transcripts (white). ACKR3, atypical chemokine receptor 3; ANXA2, annexin A2; Btnl9, butyrophilin like 9; cLEC, ceiling LEC; FISH, fluorescence in situ hybridization; fLEC, floor-lining LEC; LEC, lymphatic endothelial cell; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1; SCS, subcapsular sinus; UMAP, Uniform Manifold Approximation & Projection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32251437), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43411_rat-monoclonal-lyve-1-antibody-aly7-31020241616568.jpg)
![Immunocytochemistry/ Immunofluorescence: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] - Molecular characterization of LECs in the SCS ceiling with immunofluorescence staining.(A–C) Expression of new cLEC/cluster 2 marker genes ANXA2 (A), FABP4 (B), & CD36 (C) by RNA sequencing (left panels) & immunofluorescence staining (right panels) in Ackr4-GFP reporter mice. GFP (white) & immunofluorescence costaining for LYVE1 (green) served as markers for cLECs & fLECs, respectively. ACKR4, atypical chemokine receptor 4; ANXA2, annexin A2; CD, cluster of differentiation; cLEC, ceiling LEC; FABP4, fatty acid binding protein 4; fLEC, floor-lining LEC; GFP, green fluorescent protein; LEC, lymphatic endothelial cell; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1; SCS, subcapsular sinus; UMAP, Uniform Manifold Approximation & Projection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32251437), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43411_rat-monoclonal-lyve-1-antibody-aly7-310202416171489.jpg)
![Immunocytochemistry/ Immunofluorescence: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] - Molecular characterization of LECs in the SCS ceiling with immunofluorescence staining.(A–C) Expression of new cLEC/cluster 2 marker genes ANXA2 (A), FABP4 (B), & CD36 (C) by RNA sequencing (left panels) & immunofluorescence staining (right panels) in Ackr4-GFP reporter mice. GFP (white) & immunofluorescence costaining for LYVE1 (green) served as markers for cLECs & fLECs, respectively. ACKR4, atypical chemokine receptor 4; ANXA2, annexin A2; CD, cluster of differentiation; cLEC, ceiling LEC; FABP4, fatty acid binding protein 4; fLEC, floor-lining LEC; GFP, green fluorescent protein; LEC, lymphatic endothelial cell; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1; SCS, subcapsular sinus; UMAP, Uniform Manifold Approximation & Projection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32251437), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43411_rat-monoclonal-lyve-1-antibody-aly7-31020241618925.jpg)
![Immunocytochemistry/ Immunofluorescence: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] - Molecular characterization of LECs in the SCS ceiling with immunofluorescence staining.(A–C) Expression of new cLEC/cluster 2 marker genes ANXA2 (A), FABP4 (B), & CD36 (C) by RNA sequencing (left panels) & immunofluorescence staining (right panels) in Ackr4-GFP reporter mice. GFP (white) & immunofluorescence costaining for LYVE1 (green) served as markers for cLECs & fLECs, respectively. ACKR4, atypical chemokine receptor 4; ANXA2, annexin A2; CD, cluster of differentiation; cLEC, ceiling LEC; FABP4, fatty acid binding protein 4; fLEC, floor-lining LEC; GFP, green fluorescent protein; LEC, lymphatic endothelial cell; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1; SCS, subcapsular sinus; UMAP, Uniform Manifold Approximation & Projection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32251437), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43411_rat-monoclonal-lyve-1-antibody-aly7-310202416175280.jpg)
![Immunocytochemistry/ Immunofluorescence: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] - Molecular characterization of LECs in the SCS ceiling with RNA FISH.(A-B) Expression of new cLEC/cluster 2 marker genes Ackr3 (A) & Btnl9 (B) by RNA sequencing (left panels) & RNA FISH (right panels). As GFP fluorescence is lost during tissue processing for RNA FISH, immunofluorescence staining for ANXA2 (red) & LYVE1 (green) served as markers for cLECs & fLECs, respectively. Arrows point to cLECs expressing Ackr3 & Btnl9 transcripts (white). ACKR3, atypical chemokine receptor 3; ANXA2, annexin A2; Btnl9, butyrophilin like 9; cLEC, ceiling LEC; FISH, fluorescence in situ hybridization; fLEC, floor-lining LEC; LEC, lymphatic endothelial cell; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1; SCS, subcapsular sinus; UMAP, Uniform Manifold Approximation & Projection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32251437), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43411_rat-monoclonal-lyve-1-antibody-aly7-310202416175248.jpg)